2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Michelle Miran Kim, MD, discusses optimizing individualized treatment in cancer care.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Michelle Miran Kim, MD, associate professor, Radiation Oncology, director, Medical Student Education, co-chair, Cancer Center Neuro-Oncology Clinical Research Team, Michigan Medicine, the University of Michigan, discusses optimizing individualized treatment in cancer care.
The unprecedented rate of drug development has made it a crucial time to be involved in oncology, Kim says. Developing and executing rational clinical trials will remain important to best optimize the combination of newer therapies with existing treatments, such as radiation therapy, Kim explains.
Due to the abundance of new data and agents, a detailed multidisciplinary discourse is required to optimize care for individual patients, Kim concludes.
Related Content: